Focus
View

ADMA BIOLOGICS, INC.

ADMA · FY2025

MISALIGNED

CEO Package

$10.2M

Pay Ratio

—

Adam S. Grossman

Pay rose +29.3% while TSR fell -273 pts

ARGENX SE

ARGX · FY2024

MIXED

CEO Package

$0

Pay Ratio

—

Tim Van Hauwermeiren

Awaiting a fuller pay-performance history

Revolution Medicines, Inc.

RVMD · FY2025

MIXED

CEO Package

$14.7M

Pay Ratio

—

Mark A. Goldsmith

Pay and TSR both rose, but not in lockstep

CEOTotal Compensation — All Companies

ADMA$10.2MARGX$0KRVMD$14.7M

All values are grant-date fair value as reported in proxy statements.

Key Differences

The fastest way to read this comparison before dropping into the tables.

RVMD carries the largest package at $14.7M, about 1.4x ADMA.
ADMA reads misaligned, while ARGX looks mixed.

Pay Component Breakdown

Latest CEO package mix by company. This stays on the CEO package even if the chart above is showing Top 5 pay.

ADMA

Adam S. Grossman

$10.2M

base salary9%
stock awards40%
option awards40%
non-equity incentive compensation11%
other compensation1%

ARGX

Tim Van Hauwermeiren

$0

Component-level breakdown is unavailable for this company.

RVMD

Mark A. Goldsmith

$14.7M

base salary6%
stock awards27%
option awards61%
non-equity incentive compensation6%
other compensation0%

Quick Comparison

CompanyCEOLatest YearTotal Comp
ADMA BIOLOGICS, INC.(ADMA)Adam S. Grossman2025$10.2M
ARGENX SE(ARGX)N/AN/AN/A
Revolution Medicines, Inc.(RVMD)Mark A. Goldsmith2025$14.7M

Note: All compensation values shown are grant-date fair value as reported in proxy statements. Direct comparisons should account for differences in company size, industry, and compensation structure.

Want to know when these numbers change?

We’ll email you when these companies file a new proxy — so you can see how CEO pay, equity awards, and ratios shift before the next headline.